DHR
Danaher Corporation
NYSE · Healthcare · Medical - Diagnostics & Research · US
$207.28
−1.78%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.1B | 24.6B | 23.9B | 23.9B | 26.6B |
| Cost of Revenue | 10.4B | 9.6B | 9.7B | 9.9B | 10.5B |
| Gross Profit | 14.7B | 15.0B | 14.2B | 14.0B | 16.2B |
| Operating Expenses | |||||
| R&D Expense | 1.6B | 1.6B | 1.6B | 1.5B | 1.5B |
| SG&A Expense | 7.9B | 8.2B | 7.4B | 7.3B | 7.1B |
| General & Admin Expense | 1.9B | — | — | — | — |
| Selling & Marketing Expense | 2.1B | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 9.6B | 9.8B | 9.0B | 8.8B | 8.7B |
| Cost and Expenses | 20.0B | 19.4B | 18.7B | 18.6B | 19.1B |
| Operating Income (EBIT) | 5.1B | 5.1B | 5.2B | 5.3B | 7.5B |
| Non-Operating | |||||
| Interest Income | 104.0M | 30.0M | 117.0M | 303.0M | 41.0M |
| Interest Expense | 78.0M | 265.0M | 278.0M | 289.0M | 207.0M |
| Net Interest Income | 26.0M | (235.0M) | (161.0M) | 14.0M | (166.0M) |
| Other Non-Op Income/Expense | (365.0M) | (904.0M) | (538.0M) | (235.0M) | (390.0M) |
| Non-Operating Income (excl Interest) | 73.0M | 639.0M | 260.0M | (54.0M) | 183.0M |
| EBT (Pre-Tax Income) | 4.8B | 4.2B | 4.6B | 5.0B | 7.1B |
| Income Tax Expense | 758.0M | 619.0M | 747.0M | 823.0M | 818.0M |
| Bottom Line | |||||
| Net Income | 4.0B | 3.6B | 3.9B | 4.8B | 7.2B |
| Earnings from Cont. Ops | 4.0B | 3.6B | 3.9B | 4.2B | 6.3B |
| Earnings from Discont. Ops | — | 14.0M | — | 543.0M | 881.0M |
| Bottom Line Net Income | 4.0B | 3.6B | 3.9B | 4.7B | 7.1B |
| Per Share | |||||
| Basic EPS | $5.65 | $5.07 | $5.33 | $6.44 | $9.80 |
| Diluted EPS | $5.63 | $5.04 | $5.29 | $6.38 | $9.64 |
| Revenue Per Share | $35.60 | $34.73 | $32.66 | $32.44 | $36.74 |
| Shares | |||||
| Basic Shares Outstanding | 705.3M | 707.3M | 731.0M | 736.5M | 725.1M |
| Diluted Shares Outstanding | 707.6M | 711.0M | 737.2M | 743.1M | 737.1M |
| Profitability Metrics | |||||
| EBITDA | 7.2B | 6.9B | 7.3B | 7.5B | 9.5B |
| D&A | 2.1B | 2.4B | 2.4B | 2.2B | 2.1B |
| EBIT | 5.1B | 4.5B | 4.9B | 5.3B | 7.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026